Next steps include validation in lab models to support partnering talks, targeting underserved diseases with limited treatment options.
The strategy centers on AI-driven data, experimental evidence, and 20-year patents to de-risk assets and improve out-licensing appeal.
Potential new uses and patent filings
Sarborg Signature Intelligence work identified potential new uses, including combinations with marketed drugs; patents have been filed covering these findings.
New solid forms of existing drug compounds
CDT Equity reported new solid forms of existing drug compounds with improved stability, solubility, manufacturability versus prior forms.
Patent protection is tied to its Substance of Matter portfolio, aiming to extend commercial life through new formulations for specific patient needs.
CDT•
